KURA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KURA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Kura Oncology's shares outstanding for the quarter that ended in Mar. 2024 was 76.18 Mil.
Kura Oncology's quarterly shares outstanding increased from Dec. 2023 (74.35 Mil) to Mar. 2024 (76.18 Mil). It means Kura Oncology issued new shares from Dec. 2023 to Mar. 2024 .
Kura Oncology's annual shares outstanding increased from Dec. 2022 (68.31 Mil) to Dec. 2023 (74.35 Mil). It means Kura Oncology issued new shares from Dec. 2022 to Dec. 2023 .
The historical data trend for Kura Oncology's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kura Oncology Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Shares Outstanding (EOP) | Get a 7-Day Free Trial | 45.38 | 66.19 | 66.57 | 68.31 | 74.35 |
Kura Oncology Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Shares Outstanding (EOP) | Get a 7-Day Free Trial | 68.44 | 74.14 | 74.25 | 74.35 | 76.18 |
For the Biotechnology subindustry, Kura Oncology's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Kura Oncology's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Kura Oncology's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.
Kura Oncology (NAS:KURA) Shares Outstanding (EOP) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Thank you for viewing the detailed overview of Kura Oncology's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.
Brian T. Powl | officer: Chief Commercial Officer | C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131 |
Thomas Malley | director | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Thomas James Doyle | officer: SVP, Finance & Accounting | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Kirsten Flowers | officer: Chief Commercial Officer | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Kathleen Ford | officer: Chief Operating Officer | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Stephen Dale | officer: Chief Medical Officer | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Teresa Brophy Bair | officer: Chief Legal Officer | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Helen Louise Collins | director | TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Carol Schafer | director | 42 WHITE STREET, FOURTH FLOOR, NEW YORK NY 10013 |
Troy Edward Wilson | director, officer: President and CEO | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Marc Grasso | officer: CFO, CBO | C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO CA 92121 |
Bridget A Martell | officer: Acting Chief Medical Officer | C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268 |
James Basta | officer: Chief Legal Officer | C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK RD, SUITE 220, SAN DIEGO CA 92121 |
Diane L. Parks | director | 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540 |
Antonio Gualberto | officer: Chief Medical Officer | 245 FIRST STREET, SUITE 1820, CAMBRIDGE MA 02142 |
From GuruFocus
By sperokesalga sperokesalga • 03-01-2023
By Marketwired • 10-30-2023
By sperokesalga sperokesalga • 06-14-2023
By sperokesalga sperokesalga • 06-11-2023
By sperokesalga sperokesalga • 05-09-2023
By GuruFocus Research • 11-02-2023
By Marketwired • 08-14-2023
By sperokesalga sperokesalga • 02-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.